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Abstract
Using theoretical models based on radiobiological principles for the design of new treatment schedules for HDR and PDR 
brachytherapy, it is important to realise the impact of assumptions regarding the kinetics of repair. Extrapolations based on longer 
repair half times in a continuous LDR reference scheme may lead to the calculation of dangerously high doses for alternative HDR 
and PDR treatment schedules. We used the clinical experience obtained with conventional ERT and LDR brachytherapy in head 
and neck cancer as a clinical guideline to check the impact of the radiobiological parameters used. Biologically equivalent dose 
(BED) values for the in clinical practice of LDR brachytherapy recommended dose of 65-70 Gy (prescribed at a dose rate between 
30-50 cGy/h) are calculated as a function of the repair half time. These BED values are compared with the biological effect of 
a clinical reference dose of conventional ERT with 2 Gy/day and complete repair between the fractions. From this comparison 
of LDR and ERT treatment schedules, a range of values for the repair half times of acute or late responding tissues is demarcated 
with a reasonable fit to the clinical data. For the acute effects (or tumor control) the best fits are obtained for repair half times 
of about 0.5 h, while for late effects the repair half times are at least 1 h and can be as high as 3 h. Within these ranges of repair 
half times for acute and late effects, the outcome of‘alternative5 HDR or PDR treatment schedules are discussed. It is predominant­
ly the late reacting normal tissue with the longer repair half time for which problems will be encountered and no or only marginal 
gain is to be expected of decreasing the dose rate per pulse in PDR brachytherapy.
Keywords: Brachytherapy; Dose rate; Radiobiology; Kinetics of repair
1. Introduction
In the design of new fractionation schedules for high 
dose rate (HDR) and/or pulsed dose rate (PDR) 
brachytherapy as compared to low dose rate (LDR) 
brachytherapy [4-6,13,16], it is important to realise the 
impact of the assumed values of the repair factors in the 
calculations of isoeffective doses. Experimental and 
clinical data show a reasonable consistency in the repair 
capacity (alp ratio) for both the acute (tumor) and late 
responding tissues under the conditions of complete re­
pair. However, so far no clear picture has emerged 
about the kinetics of repair (i1/2) for the conditions of 
i
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incomplete repair during continuous irradiation. Using 
generalised values for the kinetics of repair [13] or 
values derived from hyperfractionated external beam ir­
radiation [6] or cells in culture [4], it is important to 
check the outcome of the predicted isoeffective dose 
with the clinical experience already obtained. Extrapola­
tions based on longer repair half times in a continuous
LDR reference scheme may lead to the calculation of 
unrealistic and dangerously high doses for alternative 
HDR and PDR treatment schedules. Moreover, clinical 
logistics, patient convenience and physical aspects of the 
rapid dose fall off during brachytherapy need also be 
taken into consideration.
The purpose of this paper is not to introduce a new 
radiobiological model, but to discuss consequences in
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clinical practice of predicting isoeffective doses of dif­
ferent treatment schedules for HDR, PDR and LDR 
brachytherapy. We will demonstrate the pitfalls of ex­
tending the BED concept to multifractionated HDR/ 
PDR brachytherapy, specifically with respect to:
— the choice of the reference treatment,
— the impact of the assumption of the value for the re­
pair half time,
— the application of model parameters in situations 
quite different from those in which they were 
derived.
Based on the clinical experience already obtained with 
LDR brachytherapy (dose rate <  1 Gy/h) in head and 
neck cancer and a clinical reference dose of conventional 
external beam irradiation (ERT, 2 Gy per fraction, 5 
times per week), a range of values for the repair half 
times and isoeffective doses is demarcated which show 
a reasonable fit of the clinical data. Within these ranges 
of repair half times and BED values for the acute and
late effects, the feasibility of ‘alternative* HDR (at a 
dose rate of 120 Gy/h) or PDR (dose rate 1-3 Gy/h) 
treatment schedules is discussed, where practical con­
siderations in the clinical use of brachytherapy are taken 
into account; especially with regard to the possibility of 
disconnecting the patient from the afterloading HDR or 
PDR machine during the night and/or between the 
pulses.
2. Methods
2.1. Clinical reference doses o f  LDR brachytherapy in 
head and neck cancer as compared to conventional exter­
nal beam radiation therapy
If LDR brachytherapy is used as a single modality in 
treating cancer of the oral cavity, the recommended dose
is 65-70 Gy prescribed at a reference dose rate between 
30-50 cGy/h [23,271, with as a consequence an overall 
treatment time limited to about 1 week, For such 
schedules an increase of local tumor control as com­
pared with conventional ERT alone or conventional 
ERT combined with an interstitial implant was 
observed, with an acceptable number of (late) normal 
tissue complications [3,7,18,22-24]. However, due to 
variations in dose distribution, tumor size and irradiated 
volume, a straightforward comparison of LDR 
brachytherapy and conventional ERT is not possible.
Brachytherapy is usually preferred in treating small 
tumor sizes. For any given dose of radiation, tumor con­
trol as well as normal tissue tolerance will increase with 
smaller volumes. Moreover, the physical advantage of 
the rapid dose fall off around the implanted radioactive 
sources enables high(er) doses to be delivered in the 
tumor, with relative sparing of the surrounding normal
tissues. In the different ‘systems’ providing rules for the 
source geometry and dose specification, like the M an­
chester or Paris system, the mean central dose in the tar­
get volume is about 10-15% higher than the prescribed 
(reference) dose at the tumor periphery [12,25], This 
means that if a total dose of 70 Gy LDR brachytherapy 
is prescribed at a reference dose rate of 50 cGy/hour, the 
total dose (at a higher dose rate) in the center of the tar­
get volume will be at least 77 Gy. This is in contrast with 
ERT, where the whole (homogeneously) irradiated 
volume receives the same total dose. As a consequence 
the total dose which can be applied to the tumor is lim­
ited by the tolerance dose of the surrounding normal tis­
sues included in the irradiation field. Taking these 
considerations into account one could imagine that 
from the clinical point of view the same biological effect
in terms of tumor control and (late) normal tissue com­
plications obtained with 65-77 Gy LDR brachytherapy 
at a dose rate between 30-55 cGy/h (= recommended 
dose with an uncertainty in dose and dose rate 
of + 10%) can be duplicated if it were possible to deliver 
at least the same total dose of conventional ERT (= 
64-76 Gy, if 2 Gy per fraction is used). The clinical ex­
perience of Wang et al. [38] with intra-oral cone (exter­
nal beam) irradiation for selected carcinomas of the oral 
cavity can be used as a justification for the adoption of 
this range of total doses conventional ERT between 64 
and 76 Gy. Small intra-oral lesions were irradiated with 
a relatively homogeneous external beam of 280 kV X- 
rays or 9-12 MeV electrons alone or in combination 
with external beam Cobalt60 irradiation. With this tech­
nique it was possible to deliver high doses up to approx­
imately 80 Gy (recalculated by Wang for 2 Gy per 
fraction each day, 5 days per week) to the primary lesion 
and to obtain the same level of local tumor control 
without an increase in late normal tissue complications 
as compared to LDR interstitial brachytherapy.
2.2, (In) complete repair model and BED concept (see 
also appendix)
Several authors [2,8,9,17,19,26,31] have shown that 
the LQ model and the ERD or BED concept can be ap­
plied to any type of treatment; not only to fractionated 
ERT with complete repair, but also to conditions of in­
complete repair. If fractions are spaced sufficiently to 
ensure complete repair, the biological effect of a conven­
tional (HDR) fractionation scheme of n fractions of d 
Gy each is
BEDert = nd ( I + -  —
\  a/jS /  a
where y  • 77a is a term to correct for the loss in biological 
effect due to repopulation of rapidly proliferating cells 
in tumors and early reacting normal tissues [2,10,33,34],
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T is the time during which proliferation occurs at the 
(assumed fixed) rate 7 , after any initial time lag. The fac­
tor 7 can be replaced by 7  = In 2/ r pot, where Tpot is the 
potential doubling time of the proliferating cells (assum­
ing the cell loss factor = 0). In general for late effects the 
time correction factor for repopulation is omitted [15], 
although for some late reacting normal tissues an indica­
tion for the existence of a time factor has been found 
(for review see ref. [33]).
For continuous LDR irradiation a dose rate depen­
dency has been incorporated in the LQ formalism to 
correct for incomplete repair during the irradiation
[8,17,31], where
BEDldr = d - ( I  + - - d— )  -
LDR \  (a/13) )  a
This function g depends on the total irradiation time (T) 
and the kinetics of repair represented by the repair half 
time (ii/2). Assuming that the rate of repair is a 
monoexponentional function of time and dose (rate) in­
dependent:
g = —  ( l  - - L  .[1 _  e-nT |\
p.T V #*.T 1 )
In 2
where u =---------
tm
When we invoke the LQ and BED concept for isoef­
fective dose calculations for the acute (tumor control) 
and late effects, the BED value for conventional ERT 
under the condition of complete repair must be equal to 
the BED value for LDR brachytherapy under the condi­
tion of incomplete repair, thus BEDert (acute) =
BEDLdr (acute) or BEDert O&te) — BEDldr (late)
2.3. Radiobiological parameters based on clinical data
In order to characterise the two main response 
categories (acute vs. late effects) under conditions of 
complete repair, we will use in our calculations an a/fi 
ratio of 10 for the acute reacting normal tissues and 
tumors and a/0  = 3 for the late responding tissues, 
which are generally accepted values characterising the 
fractionation sensitivity of the different types of tissues 
[15,33]. Due to uncertainties about Tpoii individual 
knowledge of a  and delay before onset of proliferation, 
it is difficult to define the correction factor for repopula­
tion in the acute reacting normal tissues and tumors. We 
will use a correction factor for repopulation as originally 
proposed by Withers in 1988 [39]. Based on an analysis 
of a large body of clinical data Withers estimated the 
rate of tumor regrowth during ERT in head and neck 
cancer. He concluded that with an extension of the treat­
ment time beyond 28 days, about 0,6 Gy per day is lost 
due to the negative effect of accelerated proliferation on
tumor control. In our calculations of the BED for a con­
ventional ERT irradiation scheme of 2 Gy/ day, 5 times 
per week, we will use 0.55 Gy/day loss after day 28 to 
correct for repopulation. For a total dose of 70 Gy in 7 
weeks, 18 days remain after a period of 28 days, which 
means that 0.55 X 1 8 -9 ,9  Gy is effectively lost in com­
pensating for concurrent repopulation. This time correc­
tion factor may be an underestimation for very fast 
proliferating tumors [10,14, 15]. With regard to the time 
of onset and rate of the accelerated repopulation after 
the start of irradiation, there is still much debate about 
the mechanism and consequences for clinical practice. 
However, the original time factor of about 0.6 Gy/day 
after a time lag period of about 4 weeks as proposed by 
Withers, has been confirmed in a number of subsequent 
analyses of clinical data in head and neck cancer 
[20,28,30], Because the total irradiation time to deliver 
70 Gy LDR is limited to about 1 week we assume that 
no cell proliferation occurs during this short treatment 
time and therefore the second term in the calculation of 
the BED value for the LDR irradiation is omitted. For 
very fast proliferating cells this may be an underestima­
tion, as has been calculated by Dale for the theoretical 
situation that the potential doubling time of tumor cells 
is <3.5 days [10].
3. Results
3.1. Isoeffective dose calculations o f  the clinical reference 
doses o f  LDR brachy therapy and conventional E R T
In Fig. 1 the biological effect in terms of BED for the 
in clinical practice recommended dose and dose rate of 
LDR brachytherapy is calculated as a function of the re­
pair half time (for the acute effects in Fig, la  the BED 
is expressed in Gyi0 assuming a/j3 =10, for the late ef­
fects in Fig. lb  the BED is expressed in Gy3 assuming 
an a//3 = 3). The recommendation of a dose of 65-70 Gy 
and a reference dose rate between 30-50 cGy/h to max­
imize local tumor control and minimize late normal tis­
sue effects, includes a dose and dose rate uncertainty 
between a minimum of 65 Gy at a dose rate of 30 cGy/h 
and a maximum of 77 Gy at 55 cGy/h. The calculated 
BED values for these minimum and maximum LDR ir­
radiation schemes are compared with a clinical reference 
dose of conventional ERT at 2 Gy/day on the right Y- 
axis (with a correction in Fig. la  for tumor repopula­
tion). The BED lines of 70 Gy LDR at 50 cGy/h (= 140
h) and the 70 Gy conventional ERT serve as reference 
lines.
As can be seen in Fig. la, a match between clinically 
equivalent schedules for the acute effects (= tumor con­
trol and acute reacting normal tissues) either given as 70 
Gy LDR at a dose rate of 50 cGy/h or 70 Gy ERT, can 
only be obtained at a repair half time of 0.2 h. Based on 
clinical experience of LDR brachytherapy and conven­
tional ERT in head and neck cancer it has been argued
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Fig. 1. (A) BED in GyJ0 as a function of the repair half time for the 
acute effects (= tumor control) with an a/fi ratio of 10 Gy. The 
calculated BED values on the left Y-axis are compared with a 
biologically equivalent total dose conventional ERT at 2 Gy/day (cor­
rected for repopulation) on the right Y-axis. The oblique lines repre­
sent the reference schemes of the in clinical practice recommended 
dose of 65 or 70 Gy LDR br achy therapy, prescribed at a dose rate be­
tween 30-50 cGy/h, with an uncertainty in dose and dose rate between 
a maximum of 77 Gy at 55 cGy/h and a minimum of 65 Gy at 30 
cGy/h. The horizontal lines are the BED lines of 64, 70 and 76 Gy con­
ventional ERT. The shaded area demarcates the range of repair half 
times and BED values where the LDR and ERT treatment schedules 
match for tumor control (= acute effects). (B) BED in Gy3 as a func­
tion of the repair half time for the late effects with an d p  ratio of 3 
Gy, Otherwise the same as in (A), with the exception that on the right 
Y-axis no correction for repopulation has been made. The shaded area 
demarcates the range of repair half times and BED values where the 
LDR and ERT treatment schedules match for late effects.
(see previous section) that it is precarious to attribute 
clinical equivalency of tumor control obtained with 65 
or 70 Gy LDR to one absolute value of 70 Gy ERT. 
Therefore, a range of total doses ERT between 64 and 
76 Gy was proposed (see Methods) to include an uncer­
tainty in total dose of conventional ERT which could 
result in the same probability of local tumor control as 
obtained with 65-70 Gy LDR brachytherapy prescribed 
at a dose rate between 30-50 cGy/h. The shaded area in 
Fig. la. demarcates values of the intrinsic repair half
times and BED values for tumor control (= acute ef­
fects) to match tumor control obtained within a range of 
total doses for conventional ERT between 64-76 Gy 
and the minimum of 65 Gy at 30 cGy/h or the maximum 
of 77 Gy at 55 cGy/h as recommended in clinical prac­
tice of LDR brachytherapy. Within the boundaries of 
this shaded area, the repair half time with the highest 
probability varies between 0.2-1 h. This is in agreement 
with most experimental data on acute effects. Moreover, 
in this way it can be easily seen that for tumors or the 
acute reacting normal tissues, a repair half time > 1.5 h 
does not provide a reasonable fit of the clinical data.
For the late effects (see Fig. lb), a match between
clinically equivalent schedules, i.e. 70 Gy LDR at 50 
cGy/h or 70 Gy ERT, can only be obtained at a repair 
half time of 1.4 h. However, if the dose rate to deliver 
70 Gy is 30 cGy/h, a much longer repair half time of 2.3
h needs to be assumed to maintain a match with the 70 
Gy ERT reference. The shaded area in Fig. lb demar­
cates values of the intrinsic repair half time and BED 
values for late effects to match late normal tissue com­
plications obtained with 64-76 Gy conventional ERT 
and a total dose of 65-70 Gy LDR brachytherapy 
prescribed at a reference dose rate between 30-50 
cGy/h. In contrast to the range of repair half times for
the acute effects within the shaded area of Fig. la (where 
a repair half time > 1.0 h is unlikely to occur), the value 
of the repair half time for the late effects has to be at 
least 1 h and can be as long as 3 h, This is not an unex­
pected finding, because most of the experimental data 
on the kinetics of repair in late normal tissues revealed 
that the half times for the late effects vary between 1 and 
2 h. We will use these shaded areas as derived in Fig. 1 
(boundaries of which are based on clinical experience 
obtained with conventional ERT and LDR brachy­
therapy in head and neck cancer), to serve as clinical 
guideline in the design of new treatment strategies for 
HDR and PDR bachytherapy and to check the impact 
of variations in the repair half time. The BED lines of 
70 Gy LDR at a dose rate of 50 cGy/h and 70 Gy ERT 
serve as reference. In this way it can be easily seen that 
it is not realistic to assume a repair half time for the late 
effects of 3 h, and to calculate subsequently an isoeffec­
tive dose for a HDR or PDR treatment schedule with 70 
Gy LDR brachytherapy at 50 cGy/h as reference treat­
ment schedule (this would imply a biologically equiva­
lent total dose of conventional ERT of > 100 Gy).
3.2. New treatment strategies: HDR and PDR brachy­
therapy
Based on practical considerations in the clinical use of 
brachytherapy, the following more convenient treat­
ment schedules are chosen:
18 fractions HDR (= 120 Gy/h) of 3.1 Gy for 6 con-
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secutive days, with 3 fractions per day and 6 h inter­
val. No irradiation during the night.
— 48 pulses of 1.4 Gy at a dose rate of 3 Gy/h con­
tinuously day and night for 6 consecutive days with 
a pulse frequency of 3 h, or
— 90 pulses of 0.7 Gy at a dose rate of 3 Gy/h during 
daytime for 6 consecutive days with a pulse frequen­
cy of 1 h. No irradiation during the night.
All these treatment schedules have the practical ad­
vantage that the patient can be disconnected from the 
afterloading PDR machine during the night and/or be­
tween the pulses. For reasons of comparison the opti­
mum PDR brachytherapy irradiation scheme as 
proposed by Brenner and Hall [4] and Fowler [13] is 
also given, namely,
— 140 pulses of 0.5 Gy continuously day and night, 
with a pulse repetition frequency of 1 h and a dose 
rate per pulse 1 Gy/h. In this way the basic assump­
tion is fulfilled that the treatment time and average
dose rate are kept unchanged as compared to 70 Gy 
LDR brachytherapy in 140 h (dose rate = 50 cGy/h).
Fig. 2 shows the different treatment strategies schemati­
cally, keeping the overall treatment time constant (= 6 
days).
In Fig. 3 we have calculated in the same way as in Fig.
1. the BED as a function of the repair time for alterna­
tive treatment strategies of HDR and PDR 
brachytherapy (for the formulas used in the different 
situations see Appendix). To prevent a significant 
change in the therapeutic ratio, which would be detec­
table in clinical practice of brachytherapy, each BED 
line has to cross shaded areas in each of Fig. 3a and b. 
For tumor control it will be an advantage if the BED
line is positioned at the top of the shaded area in Fig.
3a, for the late reacting normal tissues at the bottom of 
the shaded area in Fig. 3b. For the acute as well as for 
the late effects the BED line of 140 pulses of 0.5 Gy 
PDR overlaps almost completely the BED line of 70 Gy 
LDR at 50 cGy/h. As can hardly be noticed in this fig­
ure, but explained in detail by Fowler [16], such a PDR 
treatment schedule will be biologically more effective 
than 70 Gy LDR at 50 cGy/h if the repair half time is 
<0.5 h. However, the impact of the (lower) dose rate 
per pulse and such short half times may be somewhat 
overemphasized. Actually, for tumor control with short 
half times of repair <0.5 h, a decrease of the dose rate 
per pulse will include a therapeutic disadvantage, be­
cause a decrease in BED results in lower tumor control 
probability. For the late effects, repair half times of 
< 0,5 h are very unlikely (see shaded area in Figs. lb and 
3b). With the restriction of repair half times to the range 
of values compatible with BED values within the shaded 
area for the late effects, the dose rate per pulse becomes 
irrelevant due to the small doses per pulse. It is the dose 
per pulse and time intervals between the pulses which 
are the most important factors in sparing late normal 
tissues; especially for half times of > 2  h. For these long­
er repair half times, the late effects are no longer max­
imally spared during LDR irradiation or the standard 
PDR treatment. In contrast, a relatively large amount of 
damage can be repaired during the longer time intervals 
between the HDR fractions or PDR pulses or during the 
night when no pulses are delivered.
Thus, with the uncertainties about dose and dose rate 
in clinical practice of brachytherapy taken into account 
(reflected by the shaded areas), it seems to be safe to at­
tempt the more convenient HDR or PDR treatment 
schedules of 18 x 3.1 Gy HDR or 48 X 1.4 Gy PDR as 
an alternative to LDR brachytherapy or the standard
4
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Fig. 2. Schematic representation of alternative HDR or PDR treatment strategies as compared to a standard LDR brachytherapy treatment schedule 
of 70 Gy in 140 h (= dose rate 50 cGy/h) or the optimum PDR irradiation scheme as proposed by Brenner and Hall [41 and Fowler [131. Overall 
treatment time of 6 days is kept unchanged in all treatment schedules. For further explanation see text.
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Fig. 3. Calculated BHD values as a function of the repair half time for 
the acute effects (A) and late effects (B) for the alternative HDR or 
PDR treatment schedules as compared with the optimum PDR 
brachy therapy treatment schedule as proposed by Brenner and Hall 
[4] and Fowler [13]. The latter is the BED line of 140 pulses of 0.5 Gy
at a dose rate of 1 Gy/h, marked by the stippled line ( ......... ), which
almost completely overlaps the LDR reference line of 70 Gy at a dose 
rate of 50 cGy/h (represented by the----- marked line). The multifrac­
tionated HDR-BED line of 18 X 3.1 Gy HDR is marked by (------),
the two BED lines of the PDR treatment schedules of 48 X 1.4 Gy and
90 X 0.7 Gy at a dose rate of 3 Gy/h are marked by (-----) and
(------ )} respectively. The 70 Gy ERT reference line is the solid hori­
zontal line (------).
PDR treatment schedule. For 90 pulses of 0.7 Gy at a 
dose rate of 3 Gy/h, tumor control can be negatively af­
fected because for a repair half time <0.5 h this line is 
positioned at the bottom of the shaded area of Fig. 3a. 
In this case 90 pulses of 0.75 Gy (irrespective of the dose 
rate per pulse) would be a better option, with slightly 
negative implications in sparing the late effects.
J.3. Example o f  a potential pitfall o f  extending the BED 
concept with the assumption o f  a longer repair half time 
and a LDR reference scheme
To illustrate the possible risk of assumptions of the ki­
netics of repair in situations quite different from the one
NTCP (%)
BED (G yJ
Fig. 4. Normal tissue complication probability (%NTCP) calculated as 
a function of BED (in Gy4) for the original clinical data of Turesson 
and Thames [35] and for the theoretical situation with the assumptions 
made by Brenner et al [6]. In the first case a//3 = 4 Gy, a = 0.1 Gy_l 
and = 528 (see Table 4c in ref [35]) is used, for the latter see text.
in which they were derived, we reanalyzed the example 
Brenner et aL [6] gave in their paper ‘Optimizing the 
time course of brachytherapy and other accelerated 
radiotherapeutic regimes’. For illustrative purposes, the 
authors used late responding tissue parameters taken 
from the clinical data of Turesson and Thames [35], and 
made two main assumptions:
a slow component of repair of 4 h for the late effects, 
without any contribution of the fast component.
— a ‘generic5 continuous LDR treatment of 60 Gy in 
120 h produces a normal tissue complication proba­
bility of 20%.
Using the formulas as described previously, it can 
easily be calculated that with an or//3 ratio of 4 Gy, a re­
pair half time of 4 h and a total dose of 60 Gy LDR in 
120 h, the corresponding BEDldr value is 142 Gy4. In 
terms of a clinical reference dose of conventional ERT 
at 2 Gy/day and complete repair between the fractions,
a BEDert value of 142 Gy4 would imply that a total 
dose of 95 Gy can be delivered. Obviously, such a dose 
would not be considered as feasible in a clinical situ­
ation. Inspecting the original clinical data of Turesson 
and Thames and the derived dose-response curve for 
teleangiectasia score S:2 at 5 years, if 5 fractions of 2 
Gy/week are delivered (Fig. 3b in ref [35]), a total dose 
of 95 Gy is well exceeding the 80 Gy, which is associated 
with a complication probability rate of 100%.
In Fig. 4 we have reconstructed the original dose re­
sponse curve of Turesson and Thames [35] in terms of
® E^ert On Gy4) on the X-axis and the probability of a 
teleangiectasia score £  2 at 5 years on the Y-axis (for the
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formulas used see the Appendix). Together with this 
dose-response curve based on clinical data, we con­
structed a complete dose-response curve for the theoreti­
cal situation with the assumptions made by Brenner et 
al. [6]. For this purpose we calculated the NTCP as a
function of BEDld r  (in Gy4) using a value of 
2.5 X 106 for the parameter which was calculated 
by Brenner et al. to be the number of target cells/colony 
forming units. In the ideal situation the mathematically
calculated dose-response curve, based on assumed 
values for the different parameters characterizing the 
late reacting normal tissues, should overlap the original 
dose-response curve of Turesson and Thames, derived 
from actual clinical experience. However, the calculated 
curve for the ‘generic* continuous LDR treatment 
schedule as assumed by Brenner et al. is shifted con­
siderably by almost a factor two. This large difference is
caused in essence by assuming a high value for the repair 
half time (= 4 h) in combination with a LDR reference 
treatment schedule.
4. Discussion
Careful clinical observations will remain a prere­
quisite when new treatment options of HDR or PDR
brachytherapy based on isoeffective dose calculations 
are introduced in the clinic. Especially if generalized 
values for the half times of repair [13] or values obtained 
from cells in culture [4] or hyperfractionated external 
beam irradiation [6] are used, it is important to realise 
the impact of such values for the calculation of the isoef­
fective dose of a reference continuous LDR treatment 
schedule within the conditions of incomplete repair. The 
potential pitfall of adopting radiobiological parameters 
and to apply these values in current models for the de­
sign of new treatment strategies in clinical use has been 
clearly shown in Fig. 4.
As a clinical guideline and to check the impact of vari­
ations of the repair half time values for both the acute 
and late effects, we have compared the calculated BED
values in conditions of incomplete repair during con­
tinuous LDR brachytherapy with the biological effect of 
a clinically widely accepted reference treatment under 
the conditions of complete repair, i.e. a conventional 
ERT schedule with 2 Gy per fraction (see Fig. 1). Subse­
quently, a range of values for the repair half time of 
acute and late responding tissues is demarcated which 
reasonably can fit the clinical experience of continuous 
LDR brachytherapy and conventional ERT in head and 
neck cancer. Within the range of clinical uncertainties of 
dose and dose rate in clinical practice of LDR brachy­
therapy (reflected by the shaded areas) for the acute ef­
fects or tumor control, the best fits are obtained for re­
pair half times of about 0.5 h, while for the late effects 
the repair half times are at least 1 h and can be as high 
as 3 h. This range of values for the repair half times for
the acute and late effects is in agreement with most 
experimental data of the kinetics of repair studied in 
vitro (for review see ref. [4]) or in vivo (for review table 
see ref. [21]). As has become clear from Figs. 1 and 3, 
within these ranges of repair half times for acute and late 
effects, it is predominantly the late reacting normal tis­
sues with the longer half times of repair for which pro­
blems are expected in the introduction of PDR 
brachytherapy as an alternative to continuous LDR 
brachytherapy. In this regard, the title of the paper of 
Fowler, ‘Why shorter half times of repair lead to greater 
damage in pulsed brachytherapy’ [16], can be mis­
leading with regard to the late effects, because this state­
ment is only true if one is changing from a continuous 
LDR treatment schedule to PDR brachytherapy within 
the conditions of a fixed overall treatment time and the 
same total dose and average dose rate. For half times 
> 1.5 h, a continuous LDR treatment schedule of 70 Gy 
in 140 h has a relatively high BED value (compared with 
the biological effect of a clinical reference dose of con­
ventional ERT with 2 Gy/day and complete repair be­
tween the fractions) and for the late effects it is 
misleading to invoke biological equivalence with such a 
reference treatment schedule. The impact of the assump­
tion of even higher values up to 4 h for the repair half 
times of the late effects [6] in combination with a con­
tinuous LDR reference treatment schedule is shown in 
Fig. 4, leading to clinically unrealistic high BED values 
as compared to the actual clinical experience.
For these long repair half times, the late reacting nor­
mal tissues are no longer maximally spared during a
continuous LDR treatment regime of 70 Gy in 140 h as 
compared to other HDR and/or PDR brachytherapy 
treatment schedules with a fixed total dose and overall 
treatment time (for detailed calculations see Brenner et 
al., [6]). Moreover, we have shown in our calculations 
that, if these longer repair half times are considered for 
the late effects, there is no or little gain to be expected 
by decreasing the dose rate per pulse during PDR 
brachytherapy (due to the small doses per pulse), and 
the sparing effect for the late reacting normal tissues has 
to come from longer time intervals. In this scope it is not 
surprising that with the more convenient HDR schedule 
of 18 X 3.1 Gy or PDR schedule of 48 X 1.4 Gy at 3 
Gy/h the same or even better sparing effects of late nor­
mal tissues is to be expected as compared to a con­
tinuous LDR brachytherapy treatment schedule of 70
Gy in 140 h or the ‘standard’ PDR treatment schedule 
of 70 Gy with a pulse repetition frequency of 1 h and a 
dose rate per pulse of 1 Gy/h. Essential in our calcula­
tions is that total doses and average dose rates are not 
the same as compared with continuous LDR brachy­
therapy, which is different from the basic assumption of 
Brenner and Hall [4] and Fowler [13]. But, if theoretical 
models are used to predict isoeffective dose levels, why 
should a change in total dose and average dose rate not
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be considered? In clinical practice of external beam irra­
diation with accelerated and/or hyperfractionated treat­
ment schedules, it is now generally accepted that based 
on isoeffective dose calculations the total dose has to be 
changed in dependence of the dose per fraction and the 
overall treatment time. Therefore, there seems to be no 
reason why it should not be allowed to change the total
dose and average dose rate if PDR or even HDR 
brachytherapy treatment schedules are introduced in 
clinical practice as an alternative for LDR brachy- 
therapy.
With the introduction of accelerated and/or hyper­
fractionated irradiation schemes in clinical practice of 
external beam irradiation, the interest and research in 
the kinetics of repair has increased. In all our theoretical
calculations we assumed that the kinetics of repair is a 
mono-exponential function of time and dose rate inde­
pendent. However, extended multifractionation studies 
(both clinical and experimental in vivo) revealed that the
kinetics of repair might consist of a fast and a slow re­
pair component. The analysis of acute and late human 
skin reactions based on a bi-exponentional model as 
proposed by Thames [32], showed for the acute effects 
a possible biphasic repair rate with a fast repair compo­
nent of 0.3-0.4 h and a slow component of 1.1 and 1.3 h; 
for the late reactions this was about 0.4 h and 3.5 h,
respectively [35]. A similar trend has been found for pig 
skin [36], spinal cord [1] and lung [37]. The proportion 
of the amount of damage repaired with the fast or slow 
component varied for the different normal tissues
studied. There are no data available which indicate a 
biphasic pattern of the kinetics of repair during con­
tinuous LDR irradiation at a dose rate < 1 Gy/h, which 
is a relevant dose rate in clinical practice of LDR or 
PDR brachytherapy. Theoretically one could imagine 
that if the rate of repair indeed consists of a fast and a 
slow component during this (very) low dose rate irradia­
tion, the fast component will be able to repair a relative­
ly larger amount of damage during the protracted time 
at which the irradiation is delivered. The relative faster 
repair kinetics after continuous low dose rate irradiation 
found in vitro [30] or in vivo [11] may sustain this theo­
retical consideration, but at least indicates that one has 
to be careful with a direct translation of either one or 
two components of repair found in the ERT experimen­
tal or clinical situation to the daily practice of brachy­
therapy. More experimental data in well characterized 
and clinically relevant animal models are needed to test 
the applicability of a mono- or bi-exponential IR model 
during continuous irradiations, especially under the 
brachytherapy conditions of the rapid dose fall off.
Finally, clinical considerations about consequences of 
practical use and patient convenience are equally impor­
tant. In this regard, we have shown that, with con­
straints in the use of repair half times in mathematical 
modelling of clinical HDR and PDR treatment 
schedules, it will probably be difficult to detect any sig­
nificant difference in clinical practice between the more 
convenient HDR or PDR treatment schedules of 18 x 
3.1 Gy HDR or 48 X 1.4 Gy PDR at 3 Gy/h as com­
pared to LDR brachytherapy or the PDR treatment 
schedule as proposed by Brenner and Hall [4] and 
Fowler [13]. However, before these alternative treat­
ment options are introduced in the clinic, a thorough 
experimental investigation and a detailed knowledge of
the radiobiological repair factors for specific tissues and 
endpoints is warranted.
Appendix
Isoeffect models based on the BED concept
1. Infinite dose-rate, complete repair
BED = (nd) • (  1 + ----- I — - —
\  cv//3 /  a
BED = biological equivalent dose, 
n = the number of fractions, 
d = the dose per fraction, 
a/jS = the repair constant (= fractionation sensitiv­
ity) of the tissue involved, 
nd = the dosage factor = the total dose,
T = the time during which proliferation occurs
after any initial time lag, T  = Towet?Al -  r K, 
and Tk. is the kickoff time,
7 = the assumed constant rate at which prolifera­
tion occurs, 7 = In 2/T  oi and r pot is the aver­
age doubling time of the proliferating cells.
2. Infinite dose-rate, incomplete repair 
BED = (nd) • ( l +  - 4 - ) [ l  + An0)]) -
\  a/p /  a
A„(0 ) represents the amount of unrepaired damage, 
which depends on:
n = the number of fractions,
Ty2 = the assumed constant value of the half time at
which repair proceeds, 
t = the time between subsequent fractions, during
which repair can occur.
Special cases for /*n(0):
— when n equi-spaced fractions are given hn is 
presented by:
»  ■ 6) ■ (A ) ■ VS-)
e  = Tta = \n(2)/fi
0  = the monoexponential repair function, depend­
ing on Tm,
fi = the parameter for the kinetics of repair.
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when 2 fractions are given during day-time, with 
incomplete repair overnight, /in(9) is presented 
by:
A„(6 1,2) = 0 i + • 0
(1 + e ,)
1 -  e , • e
n
2
1 - (e,e2) 
1 -  e , e 2
nil
e , = e“'", 02 = e- "124 "
t = the time between fractions during day-time,
24 -  t = the repair time overnight.
when 3 fractions are given during day-time, with
incomplete repair overnight, hn(Q) is presented 
by:
(0 j + 02 + 0 J02)
K
1 -  010203
1 -  010203  
1 -  0 i0 203
n/3
4. Fractionated low dose-rate irradiation.
when the fractionated doses are equally spaced, 
BED is represented by:
BED = n ■ d„ • ( 1 + dn
a/ß t
+ £ ' (M,) ■ h„(Q)]
s' 0*0 =e**1" -  2 + e"***" 
(pt f«)2
dn = vtm where t„ = exposure time per fraction; 
6/n = time between fractions.
for a real scheme, fraction i, with dose d-, given
after 5/; h after fraction / -  1, a series for BED 
can be calculated as follows:
BED, = d, ■ I + di
alß
lg(pti) + g'iixti) ■ 2 • FJ
K  = ©3 • [0)02  + (1 + 0102)(1 + ®l)0 + ©2)]j 
0 ; =
^, = 0, • (1 + F, _ ,), Fx = 0 
0 .  =  e -/*0i +  f y )
t\ = the time between fraction 1 and 2 , 
t l  = the time between fraction 2 and 3, 
t3 = the repair time overnight.
for a real scheme, with fraction i, t\ h after frac 
tion i -  1 and dose a series for BED can be 
calculated as follows:
BEDi = di • ( 1 + ài
a!&
[1 + 2 . FU -
y T
a
F{ = 0 j . (1 + F{_ i), F{ = 0
0 j = e“M/j
For the total effect:
n
BED E  BE° i
/= !
3. Low dose-rate continuous irradiation
BED = d • 1 +
d
d = dose = v/, where v = dose rate; ( = irradiation time
g(lit) = 2 • (/¿t -  1 +  e~MrV0 *0 2
For the total effect:
BED = L U  l BEDi
5, Normal tissue complication probability 
— from the BED calculated for a treatment sched 
ule, the NTCP follows from:
NTCP = expHfcL ■ exp(““,BED)]
NTCP = normal tissue complication probability,
k i  = the number of tissue-rescuing units (TRUs)
initially at risk for a specific late effect.
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